JP7284490B2 - モノアミンオキシダーゼｂイメージングプローブ - Google Patents

モノアミンオキシダーゼｂイメージングプローブ Download PDF

Info

Publication number
JP7284490B2
JP7284490B2 JP2018148863A JP2018148863A JP7284490B2 JP 7284490 B2 JP7284490 B2 JP 7284490B2 JP 2018148863 A JP2018148863 A JP 2018148863A JP 2018148863 A JP2018148863 A JP 2018148863A JP 7284490 B2 JP7284490 B2 JP 7284490B2
Authority
JP
Japan
Prior art keywords
compound
group
formula
pharmaceutically acceptable
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018148863A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020023455A (ja
JP2020023455A5 (https=
Inventor
龍一 原田
祥三 古本
幸司 工藤
信行 岡村
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tohoku University NUC
Original Assignee
Tohoku University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tohoku University NUC filed Critical Tohoku University NUC
Priority to JP2018148863A priority Critical patent/JP7284490B2/ja
Priority to PCT/JP2019/030936 priority patent/WO2020032038A1/ja
Priority to EP19846498.4A priority patent/EP3835293B1/en
Priority to US17/265,988 priority patent/US12522579B2/en
Publication of JP2020023455A publication Critical patent/JP2020023455A/ja
Publication of JP2020023455A5 publication Critical patent/JP2020023455A5/ja
Application granted granted Critical
Publication of JP7284490B2 publication Critical patent/JP7284490B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2018148863A 2018-08-07 2018-08-07 モノアミンオキシダーゼｂイメージングプローブ Active JP7284490B2 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2018148863A JP7284490B2 (ja) 2018-08-07 2018-08-07 モノアミンオキシダーゼｂイメージングプローブ
PCT/JP2019/030936 WO2020032038A1 (ja) 2018-08-07 2019-08-06 モノアミンオキシダーゼｂイメージングプローブ
EP19846498.4A EP3835293B1 (en) 2018-08-07 2019-08-06 Monoamine oxidase b imaging probe
US17/265,988 US12522579B2 (en) 2018-08-07 2019-08-06 Monoamine oxidase B imaging probe

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2018148863A JP7284490B2 (ja) 2018-08-07 2018-08-07 モノアミンオキシダーゼｂイメージングプローブ

Publications (3)

Publication Number Publication Date
JP2020023455A JP2020023455A (ja) 2020-02-13
JP2020023455A5 JP2020023455A5 (https=) 2021-09-16
JP7284490B2 true JP7284490B2 (ja) 2023-05-31

Family

ID=69414845

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018148863A Active JP7284490B2 (ja) 2018-08-07 2018-08-07 モノアミンオキシダーゼｂイメージングプローブ

Country Status (4)

Country Link
US (1) US12522579B2 (https=)
EP (1) EP3835293B1 (https=)
JP (1) JP7284490B2 (https=)
WO (1) WO2020032038A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20260006897A (ko) * 2024-07-05 2026-01-13 한국과학기술연구원 신규한 mao-b 억제제 및 이의 용도

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012057312A1 (ja) 2010-10-29 2012-05-03 クリノ株式会社 タウイメージングプローブ
WO2017103257A1 (en) 2015-12-18 2017-06-22 Clino Limited Monoamine oxidase b binders for use in the treatment and the diagnostic of alzheimer disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103739605B (zh) 2009-03-23 2016-08-17 伊莱利利公司 用于检测神经障碍的显像剂
SG11201603131RA (en) 2013-10-22 2016-05-30 Clino Ltd Tau imaging probe

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012057312A1 (ja) 2010-10-29 2012-05-03 クリノ株式会社 タウイメージングプローブ
WO2017103257A1 (en) 2015-12-18 2017-06-22 Clino Limited Monoamine oxidase b binders for use in the treatment and the diagnostic of alzheimer disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CAMILLE G. WERMUTH，Ｐａｒｔ ＩＩＩ 構造活性相関研究の基礎，最新 創薬化学 上巻 THE PRACTICE OF MEDICINAL CHEMISTRY ，第1版，大塚 賢一郎 株式会社テクノミック
日薬理誌（Folia Pharmacol. Jpn.），2017年09月30日，150巻, ４号，pp.172-176

Also Published As

Publication number Publication date
US20210230139A1 (en) 2021-07-29
JP2020023455A (ja) 2020-02-13
EP3835293B1 (en) 2024-12-04
EP3835293A1 (en) 2021-06-16
EP3835293A4 (en) 2022-04-20
WO2020032038A1 (ja) 2020-02-13
US12522579B2 (en) 2026-01-13

Similar Documents

Publication Publication Date Title
RU2627694C2 (ru) Производные хинолина, визуализирующий белок тау
JP5272110B2 (ja) 新規アミロイド親和性化合物
EP2218464A1 (en) Compounds for non-invasive measurement of aggregates of amyloid peptides
JP2023525081A (ja) 診断のための新規化合物
WO2015060365A1 (ja) タウイメージングプローブ
US20080219922A1 (en) Alzheimer's Disease Imaging Agents
CN103298789A (zh) 作为τ蛋白病理成像探针的杂环化合物
JP5322180B2 (ja) フッ素およびヒドロキシ基で置換されたアルコキシ基を有するｐｅｔプローブ
JP2012511526A (ja) アミロイドベータを検出するためのベンゾチアゾールアミド
JP7284490B2 (ja) モノアミンオキシダーゼｂイメージングプローブ
KR101854228B1 (ko) 신규 아밀로이드 친화성 화합물
JP2013507345A (ja) インビボイメージング剤としてのフルマゼニルの［１８ｆ］標識類似体
KR20130136424A (ko) Ｆ-18 표지된 아밀로이드 베타 리간드의 제조 방법
JP6609868B2 (ja) 放射性ハロゲン標識ピリド［１，２−ａ］ベンゾイミダゾール誘導体化合物
US20140348748A1 (en) Beta-amyloid imaging agents, methods of manufacture, and methods of use thereof
US20260027242A1 (en) Pet radioligands for imaging glutaminyl cyclase activity
JP2021102593A (ja) タウを画像化する新規化合物
RU2778739C2 (ru) Соединения для визуализации агрегатов белка тау
JP6946412B2 (ja) タウｐｅｔ画像化リガンド
JP6966456B2 (ja) タウｐｅｔ画像化リガンド
JP2014516343A (ja) 中枢神経系の疾患のイメージング、診断及び／又は治療に使用のための化合物
HK1193815B (en) Compound having affinity for amyloid
HK1162951A1 (en) Synthesis of 18f-radiolabeled styrylpyridines from tosylate precursors and stable pharmaceutical compositions thereof
HK1162951B (en) Synthesis of 18f-radiolabeled styrylpyridines from tosylate precursors and stable pharmaceutical compositions thereof
HK1148949A (en) Use of novel compound having affinity for amyloid, and process for production of the same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210806

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210806

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220308

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220705

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221019

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230405

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230405

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230413

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230418

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230509

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230512

R150 Certificate of patent or registration of utility model

Ref document number: 7284490

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250